Component Characterized By Molecular Weight Patents (Class 424/266.1)
-
Patent number: 11406704Abstract: The present disclosure provides novel adjuvants which may be used in combination with one or more antigens to augment, modulate or enhance a host immune response to the one or more antigens. The adjuvants are based on sialic acid binding molecules and may be combined with any type of antigen. The adjuvants may be formulated for mucosal and/or intranasal administration.Type: GrantFiled: September 20, 2017Date of Patent: August 9, 2022Assignee: PNEUMAGEN LIMITEDInventors: Helen Connaris, Garry Taylor, Richard E. Randall
-
Patent number: 10279023Abstract: Use of synthetic peptides derived from Trypanosoma cruzi antigens and their use in vaccination against trypomastigote infection and Chagas disease. T. cruzi uses several surface proteins to invade the host. In their role of protection, the surface protients ensure the targeting and invasion of specific cells or tissues. A conserved region in the family of mucin-associated surface proteins (MASP) was used to analyze the expression of MASP at different points of invasion and proved to be important for host cell invasion, thus suggesting MASP as a candidate for vaccine development. A synthetic peptide, MASPsyn, was studied and showed efficacy in stimulating antibody and cytokine production necessary for resistance against the parasite.Type: GrantFiled: February 13, 2017Date of Patent: May 7, 2019Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Rosa A. Maldonado, Carylinda Serna, Igor C. Almeida
-
Patent number: 7638131Abstract: This invention relates to novel Eimeria proteins with immunogenic properties as well as to DNA sequences encoding these proteins. These proteins can be administered to poultry thereby protecting the birds against coccidiosis. In addition the DNA encoding these proteins can be used for the preparation of a vector vaccine against coccidiosis.Type: GrantFiled: May 2, 2007Date of Patent: December 29, 2009Assignee: Intervet International B.V.Inventors: Jacobus Johannes Kok, Paul van den Boogaart, Arnodus Nicolaas Vermeulen
-
Patent number: 7541039Abstract: Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain, homolog or functional derivative thereof. The method includes treating the cell-wall material with a solution capable of removing a cell-wall component such as a protein, lipoteichoic acid or carbohydrate from the cell-wall material and contacting the proteinaceous substance with the cell-wall material.Type: GrantFiled: December 9, 2005Date of Patent: June 2, 2009Assignee: Applied NanoSystems, B.V.Inventors: Cornelis Johannes Leenhouts, Ranjan Ramasamy, Anton Steen, Jan Kok, Girbe Buist, Oscar Paul Kuipers
-
Patent number: 7431936Abstract: The present invention provides the RSP-1 and RSP-2 proteins which are involved in the cytoadhesion of P. falciparum during ring-stage infection of erythrocytes, antibodies which bind to the proteins, methods of screening for a P. falciparum infection, methods of determining the infective stage of P. falciparum and vaccines for protecting individuals from Plasmodium sp. infections.Type: GrantFiled: November 29, 2002Date of Patent: October 7, 2008Assignees: Institut Pasteur, Centre National de la Recherche ScientifiqueInventors: Juerg Gysin, Bruno Pouvelle, Artur Scherf, Pierre Buffet
-
Patent number: 7378096Abstract: Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. Preferred immunogenic polypeptides include gp100, her2/neu ECD-PD, ICD and M. tuberculosis antigens. The pharmaceutical compositions of the invention can be used for the treatment or prevention of cancer or infectious disease.Type: GrantFiled: June 3, 2002Date of Patent: May 27, 2008Inventors: John R. Subjeck, Robert A. Henderson, Elizabeth A. Repasky, Latif Kazim, Xiang-Yang Wang, Masoud H. Manjili
-
Patent number: 7282210Abstract: The present invention provides a method for carrying out in vitro the complete developmental sequence culture of tissular parasites, which includes culturing the parasites in a totally defined culture medium which is an axenic . . . monophasic liquid culture medium, free of serum and free of serum-derived or cell-derived macromolecules, proteins and peptides. For obtaining amastigote forms, this medium is buffered at a pH of 5.5 to 6.5 and has an osmolarity of at least 400 milliosmoles/kg of liquid. For obtaining promastigote forms, the medium is buffered at a pH of 7 to 7.5 and has an osmolarity of at least 300 milliosmoles/kg liquid. Application to the in vitro culture of different stages of tissular parasites such as Leishmania, T. cruzi, and hamatoprotozoa is also provided.Type: GrantFiled: July 9, 2002Date of Patent: October 16, 2007Assignee: Institut de Recherche pour de Developpement (IRD)Inventor: Jean-Loup Lemesre
-
Patent number: 7230075Abstract: This invention relates to novel Eimeria proteins with immunogenic properties as well as to DNA sequences encoding these proteins. These proteins can be administered to poultry thereby protecting the birds against coccidiosis. In addition the DNA encoding these proteins can be used for the preparation of a vector vaccine against coccidiosis.Type: GrantFiled: September 14, 1999Date of Patent: June 12, 2007Assignee: Intervet International B.V.Inventors: Jacobus Johannes Kok, Paul van den Boogaart, Arnodus Nicolaas Vermeulen
-
Patent number: 7101556Abstract: The invention provides a fusion protein comprising the Plasmodium merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane antigen 1 (AMA-1), the encoding DNA sequence, the vector containing the sequence, the host cell containing the vector, and the genetic engineering method for preparing the fusion protein and the usage for producing anti-malarial vaccine. The AMA-1/MSP1 fusion protein of the present invention has excellent immunogenicity and can cause an effective immune response against Plasmodium in individuals.Type: GrantFiled: February 1, 2002Date of Patent: September 5, 2006Assignee: Second Military Medical UniversityInventor: Weiqing Pan
-
Patent number: 7094576Abstract: Compositions and methods for the detection of Taenia solium and the diagnosis of T. solium infection are described. The nucleotide and amino acid sequences of the antigenic T. solium polypeptides gp50a, gp50b and gp50c are provided. The compositions contain synthetic antigenic polypeptides of larval origin prepared using the sequences described herein. Probes and primers for the detection or amplification of T. solium nucleic acid molecules are also described. The polypeptides can be administered to a human or animal to protect against T. solium infection. In addition, the polypeptides are useful as research tools for studying T. solium and as reagents in assays for the detection of T. solium antibodies in a biological sample. The methods are sensitive and specific assays that utilize the stable recombinant or synthetic antigenic polypeptides or nucleic acid molecules encoding the larval polypeptides.Type: GrantFiled: March 30, 2001Date of Patent: August 22, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Victor C. W. Tsang, Ryan M. Greene, Patricia P. Wilkins, Kathy Hancock
-
Patent number: 7067639Abstract: Methods for improving binding of a proteinaceous substance to cell-wall material of a Gram-positive bacterium are disclosed. The proteinaceous substance includes an AcmA cell-wall binding domain, homolog or functional derivative thereof. The method includes treating the cell-wall material with a solution capable of removing a cell-wall component such as a protein, lipoteichoic acid or carbohydrate from the cell-wall material and contacting the proteinaceous substance with the cell-wall material.Type: GrantFiled: December 16, 2002Date of Patent: June 27, 2006Assignee: Applied Nanosystems B.V.Inventors: Cornelis J. Leenhouts, Ranjan Ramasamy, Anton Steen, Jan Kok, Girbe Buist, Oscar P. Kuipers
-
Patent number: 7063848Abstract: A composition for and a method of eliciting in a vertebrate a protective immune response against an eukaryotic parasite are disclosed. The method includes administering to the vertebrate a composition having a carrier group coupled to an oligosaccharide obtained from a lipoglycan found on the surface of an eukaryote. The composition is administered in an amount sufficient to elicit a protective immune response against the parasite.Type: GrantFiled: June 17, 2002Date of Patent: June 20, 2006Assignee: University of MassachusettsInventor: Lloyd H. Semprevivo
-
Patent number: 6984384Abstract: Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an infectious disease. The pharmaceutical compositions of the invention can be administered to a subject, thereby providing methods for inhibiting M. tuberculosis-infection, for inhibiting tumor growth, for inhibiting the development of a cancer, and for the treatment or prevention of infectious disease. The invention further provides a method for producing T cells directed against a tumor cell or a M. tuberculosis-infected cell, wherein a T cell is contacted with an APC that is modified to present an hsp110 or grp170 polypeptide and an immunogenic polypeptide associated with a tumor or with the M. tuberculosis-infected cell.Type: GrantFiled: September 29, 2000Date of Patent: January 10, 2006Assignee: Health Research, Inc.Inventors: John R. Subjeck, Robert A. Henderson, Elizabeth A. Repasky, Latif Kazim, Xiang-Yang Wang
-
Patent number: 6979451Abstract: Vaccines and methods for inducing an immune response in a ruminant. The vaccine composition including pathogen and tick-derived antigens and a carrier or diluent. The method for inducing an immune response in a ruminate to provide immune protection which reduces the infection of ticks by A. marginale and/or prevents the transmission of the pathogen includes the steps of administering to the ruminant an effective amount of the vaccine composition having at least one antigen member of the group comprising at least one antigen member of the group comprising (i) recombinant MSP1a surface protein antigen of A. marginale, (ii) a subunit of recombinant MSP1a surface protein antigen of A. marginale and (iii) recombinant MSP1a surface protein antigen or subunits thereof in combination with antigen preparation derived from A. marginale infected cultured tick IDE8 cells and/or other pathogen and tick-derived antigens, and a carrier or diluent.Type: GrantFiled: October 31, 2002Date of Patent: December 27, 2005Assignee: The Board of Regents for Oklahoma State UniversityInventors: Jose de Jesus de la Fuente, Katherine M. Kocan, Jose Carlos Garcia-Garcia, Edmour F. Blouin
-
Patent number: 6939549Abstract: Vaccines and methods useful to induce an immune response which is protective to reduce the severity or prevent infection by ehrlichial parasites of the species Anaplasma marginale utilizing recombinant MSP1a surface protein antigens alone or in combination with tick cell culture derived A. marginale.Type: GrantFiled: October 26, 2001Date of Patent: September 6, 2005Assignee: The Board of Regents for Oklahoma State UniversityInventors: Jose de Jesus de la Fuente, Katherine M. Kocan, Jose Carlos Garcia-Garcia, Edmour F. Blouin
-
Patent number: 6902926Abstract: The invention provides polypeptide fragments derived from TgAMA-1, nucleic acids that encode the polypeptide fragments, and TgAMA-binding polypeptides such as antibodies. Methods for using the polypeptide and nucleic acid molecules to produce vaccines are also provided. In addition the invention provides methods involving use of the polypeptides, nucleic acids, and binding polypeptides, such as antibodies, for the prevention and treatment of Toxoplasmosis.Type: GrantFiled: November 9, 2001Date of Patent: June 7, 2005Assignees: University of Vermont and State Agricultural College, McGill UniversityInventors: Gary E. Ward, Carolyn G. Conant, Brian Ward
-
Patent number: 6890536Abstract: This invention discloses purified complete microsporidian polar tube proteins and the proteins, the amino acid sequences of which are represented in the attached sequence listings as SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5. The invention discloses the genes coding these proteins and their use in the fields of diagnosis.Type: GrantFiled: January 5, 2001Date of Patent: May 10, 2005Inventors: Frédéric Delbac, Christian Vivares, Antoine Danchin
-
Patent number: 6759048Abstract: DNA sequences encoding epitopes to which sporozoite-neutralizing antibodies are directed are provided. Recombinant proteins and synthetic peptides containing Cryptosporidium parvum epitopes for inducing an antigenic response are described.Type: GrantFiled: September 6, 2001Date of Patent: July 6, 2004Assignees: North Carolina State University, Arizona Board of Regents, Washington State University RegentsInventors: Lance E. Perryman, Douglas P. Jasmer, Michael W. Riggs, Travis C. McGuire
-
Patent number: 6756043Abstract: Compositions and methods for the detection of adult Taenia solium and the diagnosis and treatment of T. solium infection are described. The compositions contain one or more adult T. solium polypeptides. The polypeptides are useful as diagnostic agents for the detection of adult tapeworm infection. More preferably, the polypeptides are T. solium glycoprotein antigens referred to herein as T. solium excretory/secretory (TS/ES) polypeptides. The most preferred TS/ES polypeptide has a molecular weight of approximately 33 kDa, 38 kDa, or 42 kDa as determined by SDS-PAGE analysis.Type: GrantFiled: February 5, 2002Date of Patent: June 29, 2004Assignee: The United States of America as represented by the Department of Health and Human Services, Centers for Disease Control and PreventionInventors: Victor C. W. Tsang, Patricia P. Wilkins, James C. Allan
-
Patent number: 6730307Abstract: Compositions and methods useful for conferring passive or active immunity to the parasite, C. parvum. A high molecular weight glycoprotein antigen isolated from C. parvum, capable of binding the mAb 3E2, was shown to harbor an epitope critical for triggering the neutralizing CSP-like reaction in the parasite. Antibodies targeted against the critical epitope were shown to possess neutralizing activity, and could be combined with other anti-C. parvum monoclonal antibodies and administered to an animal to confer passive immunity. Immunogenic compositions including the purified antigen are disclosed for use in stimulating an active immune response against C. parvum.Type: GrantFiled: April 12, 2001Date of Patent: May 4, 2004Assignees: The Arizona Board of Regents Acting on Behalf of the University of Arizona, North Carolina State UniversityInventors: Michael W. Riggs, Lance E. Perryman
-
Patent number: 6680061Abstract: The present invention relates to hydrophilic Eimeria polypeptides, DNA-fragments encoding those peptides, recombinant DNA molecules comprising such DNA-fragments, live recombinant carriers comprising such DNA-fragments or recombinant DNA molecules and host cells comprising such DNA-fragments, recombinant DNA molecules or live recombinant carriers. Furthermore, the invention relates to antibodies against the polypeptides and to coccidiosis vaccines based upon said polypeptides. The invention also relates to methods for the preparation of such antibodies and vaccines, and to methods for the detection of Eimeria parasites and antibodies against Eimeria parasites.Type: GrantFiled: December 27, 2000Date of Patent: January 20, 2004Inventors: Theodorus Cornelis Schaap, Catharina Maria Kuiper, Arnoldus Nicolaas Vermeulen
-
Patent number: 6673351Abstract: Polypeptides comprising amino acid sequences of particulate antigens isolated from various species of Leishmania protozoa, or immunogenic variants thereof, are disclosed for the treatment and clinical remission of psoriasis. Also disclosed are nucleic acid sequences encoding such polypeptides, vectors incorporating such nucleic acid sequences, methods for genetically engineering microbial host cells to produce such polypeptides, and such recombinant microbial host cells. In another embodiment, immunotherapeutic agents incorporating the polypeptides or the nucleic acid sequences are disclosed for the treatment and clinical remission of psoriasis. In another embodiment, methods for the production of the polypeptides using recombinant microbial host cells are disclosed. Finally, methods for the treatment and clinical remission of psoriasis comprising administration of a pharmaceutical composition comprising one or more of the polypeptides or one or more of the nucleic acid sequences are disclosed.Type: GrantFiled: March 16, 2001Date of Patent: January 6, 2004Assignee: Astralis, LLCInventor: Jose Antonio O'Daly
-
Patent number: 6623735Abstract: Thiol proteases having Cathepsin 1 type activity are used in the formulation of vaccines for combating helminth parasites. Preferably the protease is derived from a fluke such as Fasciola hepatica.Type: GrantFiled: May 25, 1995Date of Patent: September 23, 2003Inventors: John P. Dalton, Stuart J. Andrews
-
Patent number: 6551594Abstract: The invention relates to an ex vivo animal or challenge model as a method to identify protective (recombinant) proteins and rapidly measure protective immunity in intestinal segments directed against parasites and vaccines directed against parasitic infections. The invention further relates to vaccines directed against infection with parasites, such as Fasciola hepatica, which vaccines contain protective (recombinant) proteins identified and shown to be protective in studies using the ex vivo model. The invention further relates to protective (recombinant) proteins obtained from newly excysted juveniles (NEJ) of Fasciola hepatica. The protective (recombinant) protein corresponding to an NEJ protein has an apparent molecular weight of 32 kDa and an N-terminal amino acid sequence comprising the sequence XXDVSWPFWDRMYNY (SEQ ID NO:1).Type: GrantFiled: December 23, 1999Date of Patent: April 22, 2003Assignee: Stichting Dienst Landbouwkundig OnderzoekInventors: Florine Johanna van Milligen, Johannes Bernardus Wilhelmus Joseph Cornelissen, Bernard Adri Bokhout
-
Patent number: 6476192Abstract: Antigens for the detection of antibodies to Neospora parasites for the diagnosis of neosporosis have been identified. Recombinant antigens may be produced by expression of DNA sequences derived from Neospora caninum. Both antigens are capable of detecting antibody responses in animals experimentally inoculated with N. caninum but show no evidence of cross-reactivity with serum from animals inoculated with closely related parasites such as Toxoplasma gondii or Sarcocystis species.Type: GrantFiled: April 15, 1996Date of Patent: November 5, 2002Inventors: Nicola C. Lally, Mark C. Jenkins, Jitender P. Dubey
-
Patent number: 6458922Abstract: Transfusion of contaminated blood has become the major route of transmission for Chagas' disease. Current screening tests are insensitive and yield conflicting results, while confirmatory assays do not exist. The present invention relates to antigens and their use for serological diagnosis of Chagas' disease. More specifically, the present invention concerns assays which are able to reliably and accurately detect the presence of antibodies to various specific antigens of Trypanosoma cruzi in a highly sensitive and specific manner.Type: GrantFiled: July 16, 1999Date of Patent: October 1, 2002Assignee: Innogenetics N.V.Inventor: Maan Zrein
-
Patent number: 6368600Abstract: The present invention relates to: parasitic helminth cuticlin proteins; parasitic helminth cuticlin nucleic acid molecules, including those that encode such cuticlin proteins; antibodies raised against such cuticlin proteins; and compounds that inhibit parasitic helminth cuticlin activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic helminths.Type: GrantFiled: March 20, 2001Date of Patent: April 9, 2002Assignee: Heska CorporationInventors: Ramaswamy Chandrashekar, Tony H. Morales
-
Patent number: 6248329Abstract: The present invention relates to: parasitic helminth cuticlin proteins; parasitic helminth cuticlin nucleic acid molecules, including those that encode such cuticlin proteins; antibodies raised against such cuticlin proteins; and compounds that inhibit parasitic helminth cuticlin activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from diseases caused by parasitic helminths.Type: GrantFiled: June 1, 1999Date of Patent: June 19, 2001Inventors: Ramaswamy Chandrashekar, Tony H. Morales
-
Patent number: 6203801Abstract: The present invention relates to hydrophilic Eimeria polypeptides, DNA-fragments encoding those peptides, recombinant DNA molecules comprising such DNA-fragments, live recombinant carriers comprising such DNA-fragments or recombinant DNA molecules and host cells comprising such DNA-fragments, recombinant DNA molecules or live recombinant carriers. Furthermore, the invention relates to antibodies against the polypeptides and to coccidiosis vaccines based upon said polypeptides. The invention also relates to methods for the preparation of such antibodies and vaccines, and to methods for the detection of Eimeria parasites and antibodies against Eimeria parasites.Type: GrantFiled: October 4, 1999Date of Patent: March 20, 2001Assignee: Akzo Nobel N.V.Inventors: Theodorus Cornelis Schaap, Catharina Maria Kuiper, Arnoldus Nicolaas Vermeulen
-
Patent number: 6193971Abstract: An immunogenic protein (DV 18) isolated from lungworm Dictyocaulus viviparus including variants and fragments thereof, are described. DNA encoding such protein, methods of isolating and preparing such protein, antibodies against such protein, immunoassays using such protein, a vaccine containg such protein, and methods of immunizing a mammal with such vaccine are also described.Type: GrantFiled: January 21, 1997Date of Patent: February 27, 2001Assignee: Akzo Nobel N.V.Inventors: Joachim Hofmann, Karlheinrich Schmid